Improving oral absorption via drug-loaded nanocarriers: Absorption mechanisms, intestinal models and rational fabrication

Current Drug Metabolism

Volumn 14, Issue 1, 2013, Pages 28-56

  Shahbazi, Mohammad Ali ^a,b   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cell cultures; Drug delivery; In vitro; Intestinal drug absorption; Nanocarriers; Permeability

Indexed keywords

AMILORIDE; CYCLOSPORIN; DRUG CARRIER; GENISTEIN; GUAIFENESIN; KETOPROFEN; LIPOSOME; MONENSIN; NANOCARRIER; NANOPARTICLE; NICOTINIC ACID; NYSTATIN; POLYMER; PROTAMINE; VERAPAMIL;

ARTICLE; CELL LINE; CELL TRANSPORT; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; EMULSION; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; HUMAN; HYDROGEL; MEMBRANE PERMEABILITY; MICELLE; NANOTECHNOLOGY; NONHUMAN; TOXICITY TESTING;

EID: 84871342859     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920013804545133     Document Type: Article

References (284)

1. Hamidi, M.; Shahbazi, M. A.; Rostamizadeh, K. Copolymers: Efficient Carriers for Intelligent Nanoparticulate Drug Targeting and Gene Therapy. Macromol. Biosci., 2011, 12, 144-164.
2. Goldberg, M.; Gomez-Orellana, I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov., 2003, 2, 289-295.
3. Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J. The performance of nanocarriers for transmucosal drug delivery. Expert Opin. Drug Deliv., 2006, 3, 463-478.
4. Chen, M. C.; Sonaje, K.; Chen, K. J.; Sung, H. W. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials, 2011, 32, 9826-9838.
5. Artursson, P.; Lindmark, T.; Davis, S. S.; Illum, L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res., 1994, 11, 1358-1361.
6. Evans, D. F.; Pye, G.; Bramley, R.; Clark, A. G.; Dyson, T. J.; Hardcastle, J. D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut, 1988, 29, 1035-1041.
7. Atuma, C.; Strugala, V.; Allen, A.; Holm, L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 280, G922-929.
8. Wang, R.; Tian, Z.; Chen, L. Nano-encapsulations liberated from barley protein microparticles for oral delivery of bioactive compounds. Int. J. Pharm., 2011, 406, 153-162.
9. Malik, D. K.; Baboota, S.; Ahuja, A.; Hasan, S.; Ali, J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv., 2007, 4, 141-151.
10. Balimane, P. V.; Pace, E.; Chong, S.; Zhu, M.; Jemal, M.; Pelt, C. K. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. J. Pharm. Biomed. Anal., 2005, 39, 8-16.
11. Guan, P.; Lu, Y.; Qi, J.; Niu, M.; Lian, R.; Hu, F.; Wu, W. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int. J. Nanomed., 2011, 6, 965-974.
12. Kurtoglu, Y. E.; Navath, R. S.; Wang, B.; Kannan, S.; Romero, R.; Kannan, R. M. Poly (amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials, 2009, 30, 2112-2121.
13. Miret, S.; Abrahamse, L.; de Groene, E. M. Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J. Biomol. Screen., 2004, 9, 598-606.
14. Avdeef, A. Physicochemical profiling (solubility, permeability and charge state). Curr. Top. Med. Chem., 2001, 1, 277-351.
15. Alsenz, J.; Haenel, E. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm. Res., 2003, 20, 1961-1969.
16. Avdeef, A.; Tsinman, O. PAMPA - a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 2006, 28, 43-50.
17. Vllasaliu, D.; Fowler, R.; Garnett, M.; Eaton, M.; Stolnik, S. Barrier characteristics of epithelial cultures modelling the airway and intestinal mucosa: A comparison. Biochem. Biophys. Res. Commun., 2011, 415, 579-585.
18. Ozcan, O.; Irmak, M. K.; Dalcik, H.; Karaoz, E.; Kubar, A.; Koylu, H. Ultrastructural changes in rat Paneth and goblet cells after the administration of interferon-alpha. Acta Physiol. Hung, 1996, 84, 81-88.
19. Azzali, G. Structure, lymphatic vascularization and lymphocyte migration in mucosa-associated lymphoid tissue. Immunol. Rev., 2003, 195, 178-189.
20. Zhang, Z.; Bu, H.; Gao, Z.; Huang, Y.; Gao, F.; Li, Y. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int. J. Pharm., 2011, 394, 147-153.
21. Sadekar, S.; Ghandehari, H. Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug delivery. Adv. Drug Deliv. Rev., 2012, 64, 571-88.
22. Mishra, B.; Patel, B. B.; Tiwari, S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine, 2010, 6, 9-24.
23. Irache, J. M.; Esparza, I.; Gamazo, C.; Agueros, M.; Espuelas, S. Nanomedicine: novel approaches in human and veterinary therapeutics. Vet. Parasitol., 2011, 180, 47-71.
24. Arangoa, M. A.; Campanero, M. A.; Renedo, M. J.; Ponchel, G.; Irache, J. M. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm. Res., 2001, 18, 1521-1527.
25. Win, K. Y.; Feng, S. S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials, 2005, 26, 2713-2722.
26. Agueros, M.; Ruiz-Gaton, L.; Vauthier, C.; Bouchemal, K.; Espuelas, S.; Ponchel, G.; Irache, J. M. Combined hydroxypropyl-betacyclodextrin and poly (anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur. J. Pharm. Sci., 2009, 38, 405-413.
27. Agueros, M.; Zabaleta, V.; Espuelas, S.; Campanero, M. A.; Irache, J. M. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly (anhydride) nanoparticles. J. Control. Release, 2010, 145, 2-8.
28. Dressman, J. B.; Thelen, K.; Jantratid, E. Towards quantitative prediction of oral drug absorption. Clin. Pharmacokinet., 2008, 47, 655-667.
29. Ramesan, R. M.; Sharma, C. P. Challenges and advances in nanoparticle-based oral insulin delivery. Expert Rev. Med. Devices, 2009, 6, 665-676.
30. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J. P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond), 2010, 5, 287-306.
31. Shakweh, M.; Besnard, M.; Nicolas, V.; Fattal, E. Poly (lactide-coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm., 2005, 61, 1-13.
32. des Rieux, A.; Fievez, V.; Theate, I.; Mast, J.; Preat, V.; Schneider, Y. J. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci., 2007, 30, 380-391.
33. Jung, T.; Kamm, W.; Breitenbach, A.; Hungerer, K. D.; Hundt, E.; Kissel, T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly (vinyl alcohol)-graft-poly (lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res., 2001, 18, 352-360.
34. Khutoryanskiy, V. V. Advances in mucoadhesion and mucoadhesive polymers. Macromol. Biosci., 2011, 11, 748-764.
35. Dunnhaupt, S.; Barthelmes, J.; Hombach, J.; Sakloetsakun, D.; Arkhipova, V.; Bernkop-Schnurch, A. Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int. J. Pharm., 2011, 408, 191-199.
36. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y. J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release, 2006, 116, 1-27.
37. Lavelle, E. C. Lectins and microparticles for enhanced oral vaccination. Methods, 2006, 38, 84-89.
38. Linehan, S. A. The mannose receptor is expressed by subsets of APC in non-lymphoid organs. BMC Immunol., 2005, 6, 4.
39. Russell-Jones, G. J.; Veitch, H.; Arthur, L. Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int. J. Pharm., 1999, 190, 165-174.
40. Yoo, H. S.; Park, T. G. Biodegradable Nanoparticles Containing Protein-Fatty Acid Complexes for Oral Delivery of Salmon Calcitonin. J. Pharmaceut. Sci., 2003, 93, 488-495.
41. Yamanaka, Y. J.; Leong, K. W. Engineering strategies to enhance nanoparticle-mediated oral delivery. J. Biomater Sci. Polym. Ed, 2008, 19, 1549-1570.
42. Pappenheimer, J. R. Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamster. J. Membr. Biol., 1987, 100, 137-148.
43. Salamat-Miller, N.; Johnston, T. P. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm., 2005, 294, 201-216.
44. Yeh, T. H.; Hsu, L. W.; Tseng, M. T.; Lee, P. L.; Sonjae, K.; Ho, Y. C.; Sung, H. W. Mechanism and consequence of chitosanmediated reversible epithelial tight junction opening. Biomaterials, 2011, 32, 6164-6173.
45. Mi, F. L.; Wu, Y. Y.; Lin, Y. H.; Sonaje, K.; Ho, Y. C.; Chen, C. T.; Juang, J. H.; Sung, H. W. Oral delivery of peptide drugs using nanoparticles self-assembled by poly (gamma-glutamic acid) and a chitosan derivative functionalized by trimethylation. Bioconjug. Chem., 2008, 19, 1248-1255.
46. Hilgendorf, C.; Spahn-Langguth, H.; Regardh, C. G.; Lipka, E.; Amidon, G. L.; Langguth, P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside-and outside-directed carrier-mediated transport. J. Pharm. Sci., 2000, 89, 63-75.
47. Shah, P.; Jogani, V.; Bagchi, T.; Misra, A. Role of Caco-2 cell monolayers in prediction of intestinal drug absorption. Biotechnol. Prog., 2006, 22, 186-198.
48. van Breemen, R. B.; Li, Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin. Drug Metab. Toxicol., 2005, 1, 175-185.
49. Maksymowych, A. B.; Simpson, L. L. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem., 1998, 273, 21950-21957.
50. Rousset, M. The human colon carcinoma cell lines HT-29 and Caco-2: two in vitro models for the study of intestinal differentiation. Biochimie, 1986, 68, 1035-1040.
51. Horie, K.; Tang, F.; Borchardt, R. T. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm. Res., 2003, 20, 161-168.
52. Meinl, W.; Ebert, B.; Glatt, H.; Lampen, A. Sulfotransferase forms expressed in human intestinal Caco-2 and TC7 cells at varying stages of differentiation and role in benzo [a]pyrene metabolism. Drug Metab. Dispos., 2008, 36, 276-283.
53. Raeissi, S. D.; Guo, Z.; Dobson, G. L.; Artursson, P.; Hidalgo, I. J. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm. Res., 1997, 14, 1019-1025.
54. Tian, J. Q.; Quaroni, A. Dissociation between growth arrest and differentiation in Caco-2 subclone expressing high levels of sucrase. Am. J. Physiol., 1999, 276, G1094-1104.
55. Li, H.; Chung, S. J.; Shim, C. K. Characterization of the transport of uracil across Caco-2 and LLC-PK1 cell monolayers. Pharm. Res., 2002, 19, 1495-1501.
56. Tavelin, S.; Taipalensuu, J.; Hallbook, F.; Vellonen, K. S.; Moore, V.; Artursson, P. An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes. Pharm. Res., 2003, 20, 373-381.
57. Tavelin, S.; Taipalensuu, J.; Soderberg, L.; Morrison, R.; Chong, S.; Artursson, P. Prediction of the oral absorption of lowpermeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res., 2003, 20, 397-405.
58. Kaoutzani, P.; Parkos, C. A.; Delp-Archer, C.; Madara, J. L. Isolation of plasma membrane fractions from the intestinal epithelial model T84. Am. J. Physiol., 1993, 264, C1327-1335.
59. Steensma, A.; Noteborn, H. P.; Kuiper, H. A. Comparison of Caco-2, IEC-18 and HCEC cell lines as a model for intestinal absorption of genistein, daidzein and their glycosides. Environ. Toxicol. Pharmacol., 2004, 16, 131-139.
60. Basavappa, S.; Vulapalli, S. R.; Zhang, H.; Yule, D.; Coon, S.; Sundaram, U. Chloride channels in the small intestinal cell line IEC-18. J. Cell Physiol., 2005, 202, 21-31.
61. Cencic, A.; Langerholc, T. Functional cell models of the gut and their applications in food microbiology - a review. Int. J. Food Microbiol., 2010, 141 Suppl 1, S4-14.
62. Lennernas, H. Human intestinal permeability. J. Pharm. Sci., 1998, 87, 403-410.
63. Balimane, P. V.; Chong, S. Cell culture-based models for intestinal permeability: a critique. Drug Discov. Today, 2005, 10, 335-343.
64. Balimane, P. V.; Chong, S.; Morrison, R. A. Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol. Methods, 2000, 44, 301-312.
65. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.
66. Pidgeon, C. Solid phase membrane mimetics: immobilized artificial membranes. Enzyme Microb. Technol., 1990, 12, 149-150.
67. Seo, P. R.; Teksin, Z. S.; Kao, J. P.; Polli, J. E. Lipid composition effect on permeability across PAMPA. Eur. J. Pharm. Sci., 2006, 29, 259-268.
68. Koljonen, M.; Rousu, K.; Cierny, J.; Kaukonen, A. M.; Hirvonen, J. Transport evaluation of salicylic acid and structurally related compounds across Caco-2 cell monolayers and artificial PAMPA membranes. Eur. J. Pharm. Biopharm., 2008, 70, 531-538.
69. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem., 1998, 41, 1007-1010.
70. Youdim, K. A.; Avdeef, A.; Abbott, N. J. In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov. Today, 2003, 8, 997-1003.
71. Avdeef, A.; Artursson, P.; Neuhoff, S.; Lazorova, L.; Grasjo, J.; Tavelin, S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa (flux) method. Eur. J. Pharm. Sci., 2005, 24, 333-349.
72. Avdeef, A. The rise of PAMPA. Expert Opin. Drug Metab. Toxicol., 2005, 1, 325-342.
73. Chen, X.; Murawski, A.; Patel, K.; Crespi, C. L.; Balimane, P. V. A novel design of artificial membrane for improving the PAMPA model. Pharm. Res., 2008, 25, 1511-1520.
74. Sugano, K.; Nabuchi, Y.; Machida, M.; Aso, Y. Prediction of human intestinal permeability using artificial membrane permeability. Int. J. Pharm., 2003, 257, 245-251.
75. Hiremath, P. S.; Soppimath, K. S.; Betageri, G. V. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int. J. Pharm., 2009, 380, 96-104.
76. Bermejo, M.; Avdeef, A.; Ruiz, A.; Nalda, R.; Ruell, J. A.; Tsinman, O.; Gonzalez, I.; Fernandez, C.; Sanchez, G.; Garrigues, T. M.; Merino, V. PAMPA - a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci., 2004, 21, 429-441.
77. Behrens, I.; Kissel, T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? Eur. J. Pharm. Sci., 2003, 19, 433-442.
78. Gao, F.; Zhang, Z.; Bu, H.; Huang, Y.; Gao, Z.; Shen, J.; Zhao, C.; Li, Y. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. J. Control. Release, 2011, 149, 168-174.
79. Volpe, D. A. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med. Chem., 2011, 3, 2063-2077.
80. Sandberg, A. S. The use of caco-2 cells to estimate fe absorption in humans - a critical appraisal. Int. J. Vitam. Nutr. Res., 2011, 80, 307-313.
81. Nordskog, B. K.; Phan, C. T.; Nutting, D. F.; Tso, P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv. Drug Deliv. Rev., 2001, 50, 21-44.
82. Trotter, P. J.; Storch, J. Fatty acid esterification during differentiation of the human intestinal cell line Caco-2. J. Biol. Chem., 1993, 268, 10017-10023.
83. Yanez, J. A.; Wang, S. W.; Knemeyer, I. W.; Wirth, M. A.; Alton, K. B. Intestinal lymphatic transport for drug delivery. Adv. Drug Deliv. Rev., 2011, 63, 923-942.
84. Hunter, J.; Hirst, B. H.; Simmons, N. L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res., 1993, 10, 743-749.
85. Sun, D.; Lennernas, H.; Welage, L. S.; Barnett, J. L.; Landowski, C. P.; Foster, D.; Fleisher, D.; Lee, K. D.; Amidon, G. L. Comparison of human duodenum and Caco-2 gene expression profiles for 12, 000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res., 2002, 19, 1400-1416.
86. Anderle, P.; Huang, Y.; Sadee, W. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. Eur. J. Pharm. Sci., 2004, 21, 17-24.
87. Krishna, G.; Chen, K.; Lin, C.; Nomeir, A. A. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int. J. Pharm., 2001, 222, 77-89.
88. Saha, P.; Kou, J. H. Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur. J. Pharm. Biopharm., 2002, 54, 319-324.
89. Nagahara, N.; Tavelin, S.; Artursson, P. Contribution of the paracellular route to the pH-dependent epithelial permeability to cationic drugs. J. Pharm. Sci., 2004, 93, 2972-2984.
90. Neuhoff, S.; Ungell, A. L.; Zamora, I.; Artursson, P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res., 2003, 20, 1141-1148.
91. Augustijns, P.; Mols, R. HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. J. Pharm. Biomed. Anal., 2004, 34, 971-978.
92. Bogman, K.; Erne-Brand, F.; Alsenz, J.; Drewe, J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J. Pharm. Sci., 2003, 92, 1250-1261.
93. Behrens, I.; Kamm, W.; Dantzig, A. H.; Kissel, T. Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. J. Pharm. Sci., 2004, 93, 1743-1754.
94. Palm, K.; Luthman, K.; Ros, J.; Grasjo, J.; Artursson, P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J. Pharmacol. Exp. Ther., 1999, 291, 435-443.
95. Adson, A.; Burton, P. S.; Raub, T. J.; Barsuhn, C. L.; Audus, K. L.; Ho, N. F. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J. Pharm. Sci., 1995, 84, 1197-1204.
96. Jevprasesphant, R.; Penny, J.; Attwood, D.; D'Emanuele, A. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J. Control. Release, 2004, 97, 259-267.
97. Sweet, D. M.; Kolhatkar, R. B.; Ray, A.; Swaan, P.; Ghandehari, H. Transepithelial transport of PEGylated anionic poly (amidoamine) dendrimers: implications for oral drug delivery. J. Control. Release, 2009, 138, 78-85.
98. Pabla, D.; Akhlaghi, F.; Zia, H. Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line. Eur. J. Pharm. Sci, 2010, 40, 466-472.
99. Liao, C. D.; Hung, W. L.; Jan, K. C.; Yeh, A. I.; Ho, C. T.; S., L. S. H. L. Nano/sub-microsized lignan glycosides from sesame meal exhibit higher transport and absorption efficiency in Caco-2 cell monolayer. Food Chem., 2010, 119, 896-902.
100. Zhao, S.; Dai, W.; He, B.; Wang, J.; He, Z.; Zhang, X.; Zhang, Q. Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J. Control. Release, 2012, 158(3), 413-23.
101. Zheng, X.; Polli, J. E. Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. Int. J. Pharm., 2010, 396, 111-118.
102. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J. P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release, 2009, 140, 174-181.
103. Garmann, D.; Warnecke, A.; Kalayda, G. V.; Kratz, F.; Jaehde, U. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. J. Control. Release, 2008, 131, 100-106.
104. Chen, M. C.; Wong, H. S.; Lin, K. J.; Chen, H. L.; Wey, S. P.; Sonaje, K.; Lin, Y. H.; Chu, C. Y.; Sung, H. W. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials, 2009, 30, 6629-6637.
105. McClean, S.; Prosser, E.; Meehan, E.; O'Malley, D.; Clarke, N.; Ramtoola, Z.; Brayden, D. Binding and uptake of biodegradable poly-DL-lactide micro-and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci., 1998, 6, 153-163.
106. Liechty, W. B.; Caldorera-Moore, M.; Phillips, M. A.; Schoener, C.; Peppas, N. A. Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. J. Control. Release, 2011, 155, 119-127.
107. Blanchette, J.; Peppas, N. A. Oral chemotherapeutic delivery: design and cellular response. Ann. Biomed. Eng., 2005, 33, 142-149.
108. Blanchette, J.; Peppas, N. A. Cellular evaluation of oral chemotherapy carriers. J. Biomed. Mater. Res. A, 2005, 72, 381-388.
109. Brayden, D. J. Oral vaccination in man using antigens in particles: current status. Eur. J. Pharm. Sci., 2001, 14, 183-189.
110. Gullberg, E.; Leonard, M.; Karlsson, J.; Hopkins, A. M.; Brayden, D.; Baird, A. W.; Artursson, P. Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun., 2000, 279, 808-813.
111. Kesisoglou, F.; Schmiedlin-Ren, P.; Fleisher, D.; Zimmermann, E. M. Adenoviral transduction of enterocytes and M-cells using in vitro models based on Caco-2 cells: the coxsackievirus and adenovirus receptor (CAR) mediates both apical and basolateral transduction. Mol. Pharm., 2010, 7, 619-629.
112. Brayden, D. J.; Baird, A. W. Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. Adv. Drug Deliv. Rev., 2004, 56, 721-726.
113. Florence, A. T. Issues in oral nanoparticle drug carrier uptake and targeting. J. Drug Target, 2004, 12, 65-70.
114. Shakya, P.; Madhav, N. V.; Shakya, A. K.; Singh, K. Palatal mucosa as a route for systemic drug delivery: A review. J. Control. Release, 2011, 151, 2-9.
115. Meaney, C.; O'Driscoll, C. Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models. Eur. J. Pharm. Sci., 1999, 8, 167-175.
116. Wikman, A.; Karlsson, J.; Carlstedt, I.; Artursson, P. A drug absorption model based on the mucus layer producing human intestinal goblet cell line HT29-H. Pharm. Res., 1993, 10, 843-852.
117. Keely, S.; Rullay, A.; Wilson, C.; Carmichael, A.; Carrington, S.; Corfield, A.; Haddleton, D. M.; Brayden, D. J. In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers. Pharm. Res., 2005, 22, 38-49.
118. Behrens, I.; Pena, A. I.; Alonso, M. J.; Kissel, T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res., 2002, 19, 1185-1193.
119. Chen, X. M.; Elisia, I.; Kitts, D. D. Defining conditions for the coculture of Caco-2 and HT29-MTX cells using Taguchi design. J. Pharmacol. Toxicol. Methods, 2010, 61, 334-342.
120. Adachi, Y.; Suzuki, H.; Sugiyama, Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm. Res., 2003, 20, 1163-1169.
121. Vogel, U.; Sandvig, K.; van Deurs, B. Expression of caveolin-1 and polarized formation of invaginated caveolae in Caco-2 and MDCK II cells. J. Cell Sci., 1998, 111(Pt 6), 825-832.
122. Lazorova, L.; Hubatsch, I.; Ekegren, J. K.; Gising, J.; Nakai, D.; Zaki, N. M.; Bergstrom, C. A.; Norinder, U.; Larhed, M.; Artursson, P. Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors. J. Pharm. Sci., 2011, 100, 3763-3772.
123. Madara, J. L.; Stafford, J.; Dharmsathaphorn, K.; Carlson, S. Structural analysis of a human intestinal epithelial cell line. Gastroenterology, 1987, 92, 1133-1145.
124. Turco, L.; Catone, T.; Caloni, F.; Di Consiglio, E.; Testai, E.; Stammati, A. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human? Toxicol. In Vitro, 2011, 25, 13-20.
125. Zucco, F.; Batto, A. F.; Bises, G.; Chambaz, J.; Chiusolo, A.; Consalvo, R.; Cross, H.; Dal Negro, G.; de Angelis, I.; Fabre, G.; Guillou, F.; Hoffman, S.; Laplanche, L.; Morel, E.; Pincon-Raymond, M.; Prieto, P.; Turco, L.; Ranaldi, G.; Rousset, M.; Sambuy, Y.; Scarino, M. L.; Torreilles, F.; Stammati, A. An inter-laboratory study to evaluate the effects of medium composition on the differentiation and barrier function of Caco-2 cell lines. Altern. Lab Anim., 2005, 33, 603-618.
126. Crespi, C. L.; Fox, L.; Stocker, P.; Hu, M.; Steimel, D. T. Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression. Eur. J. Pharm. Sci., 2000, 12, 63-68.
127. Swarnakar, N. K.; Jain, A. K.; Singh, R. P.; Godugu, C.; Das, M.; Jain, S. Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials, 2011, 32, 6860-6874.
128. Yang, C. H.; Glover, K. P.; Han, X. Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol. Sci., 2011, 117, 294-302.
129. Tang, F.; Horie, K.; Borchardt, R. T. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm. Res., 2002, 19, 773-779.
130. Singh, R.; Singh, S.; Lillard, J. W., Jr. Past, present, and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci., 2008, 97, 2497-2523.
131. Chakraborty, S.; Shukla, D.; Mishra, B.; Singh, S. Lipid - an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm., 2009, 73, 1-15.
132. Rajpurohit, H.; Sharma, P.; Sharma, S.; Bhandari, A. Polymers for colon targeted drug delivery. Indian J. Pharm. Sci., 2011, 72, 689-696.
133. Das, S.; Chaudhury, A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm-SciTech., 2011, 12, 62-76.
134. Kohli, K.; Chopra, S.; Dhar, D.; Arora, S.; Khar, R. K. Selfemulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov. Today, 2011, 15, 958-965.
135. Jabr-Milane, L.; van Vlerken, L.; Devalapally, H.; Shenoy, D.; Komareddy, S.; Bhavsar, M.; Amiji, M. Multi-functional nanocarriers for targeted delivery of drugs and genes. J. Control. Release, 2008, 130, 121-128.
136. Fricker, G.; Kromp, T.; Wendel, A.; Blume, A.; Zirkel, J.; Rebmann, H.; Setzer, C.; Quinkert, R. O.; Martin, F.; Muller-Goymann, C. Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res., 2010, 27, 1469-1486.
137. Lai, S. K.; Wang, Y. Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev., 2009, 61, 158-171.
138. Linnankoski, J.; Makela, J.; Palmgren, J.; Mauriala, T.; Vedin, C.; Ungell, A. L.; Lazorova, L.; Artursson, P.; Urtti, A.; Yliperttula, M. Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models. J. Pharm. Sci., 2010, 99, 2166-2175.
139. Aungst, B. J. Intestinal permeation enhancers. J. Pharm. Sci., 2000, 89, 429-442.
140. Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano, 2009, 3, 16-20.
141. Singh, R.; Lillard, J. W., Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86, 215-223.
142. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol. Life Sci., 2009, 66, 2873-2896.
143. Prego, C.; Torres, D.; Alonso, M. J. The potential of chitosan for the oral administration of peptides. Expert Opin. Drug Deliv., 2005, 2, 843-854.
144. Huang, M.; Khor, E.; Lim, L. Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res., 2004, 21, 344-353.
145. Lin, Y. H.; Chang, C. H.; Wu, Y. S.; Hsu, Y. M.; Chiou, S. F.; Chen, Y. J. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials, 2009, 30, 3332-3342.
146. Sandri, G.; Bonferoni, M. C.; Rossi, S.; Ferrari, F.; Boselli, C.; Caramella, C. Insulin-loaded nanoparticles based on N-trimethyl chitosan: in vitro (Caco-2 model) and ex vivo (excised rat jejunum, duodenum, and ileum) evaluation of penetration enhancement properties. AAPS PharmSciTech., 2010, 11, 362-371.
147. Kumari, A.; Yadav, S. K.; Yadav, S. C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces, 2010, 75, 1-18.
148. De Jong, W. H.; Borm, P. J. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomedicine, 2008, 3, 133-149.
149. Italia, J. L.; Bhatt, D. K.; Bhardwaj, V.; Tikoo, K.; Kumar, M. N. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Control. Release, 2007, 119, 197-206.
150. Hariharan, S.; Bhardwaj, V.; Bala, I.; Sitterberg, J.; Bakowsky, U.; Ravi Kumar, M. N. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm. Res., 2006, 23, 184-195.
151. Slomkowski, S.; Gosecki, M. Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery. Curr. Pharm. Biotechnol., 2011, 12, 1823-1839.
152. Petkar, K. C.; Chavhan, S. S.; Agatonovik-Kustrin, S.; Sawant, K. K. Nanostructured materials in drug and gene delivery: a review of the state of the art. Crit. Rev. Ther. Drug Carrier Syst., 2011, 28, 101-164.
153. Wang, J. J.; Zeng, Z. W.; Xiao, R. Z.; Xie, T.; Zhou, G. L.; Zhan, X. R.; Wang, S. L. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine, 2011, 6, 765-774.
154. Jain, A. K.; Das, M.; Swarnakar, N. K.; Jain, S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit. Rev. Ther. Drug Carrier Syst., 2011, 28, 1-45.
155. Irache, J. M.; Salman, H. H.; Gomez, S.; Espuelas, S.; Gamazo, C. Poly (anhydride) nanoparticles as adjuvants for mucosal vaccination. Front Biosci. (Schol Ed), 2010, 2, 876-890.
156. Graf, A.; McDowell, A.; Rades, T. Poly (alkylcyanoacrylate) nanoparticles for enhanced delivery of therapeutics - is there real potential? Expert Opin. Drug Deliv., 2009, 6, 371-387.
157. Mesiha, M. S.; Sidhom, M. B.; Fasipe, B. Oral and subcutaneous absorption of insulin poly (isobutylcyanoacrylate) nanoparticles. Int. J. Pharm., 2005, 288, 289-293.
158. Feng, S. S.; Mei, L.; Anitha, P.; Gan, C. W.; Zhou, W. Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials, 2009, 30, 3297-3306.
159. Yang, F.; Jin, C.; Jiang, Y.; Li, J.; Di, Y.; Ni, Q.; Fu, D. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev., 2011, 37, 633-642.
160. Peppas, N. A.; Thomas, J. B.; McGinty, J. Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption. J. Biomater. Sci. Polym. Ed, 2009, 20, 1-20.
161. Cheddadi, M.; Lopez-Cabarcos, E.; Slowing, K.; Barcia, E.; Fernandez-Carballido, A. Cytotoxicity and biocompatibility evaluation of a poly (magnesium acrylate) hydrogel synthesized for drug delivery. Int. J. Pharm., 2011, 413, 126-133.
162. Bardajeea, G. R.; Ali Pourjavadi, A.; Soleyman, R. Novel nanoporous hydrogel as a carrier matrix for oral delivery of tetracycline hydrochloride. Colloids Surf. A Physicochem. Eng. Asp., 2011, 392, 16-24.
163. Patel, V. R.; Amiji, M. M. Preparation and characterization of freeze-dried chitosan-poly (ethylene oxide) hydrogels for sitespecific antibiotic delivery in the stomach. Pharm. Res., 1996, 13, 588-593.
164. Basak, P.; Adhikari, B. Poly (vinyl alcohol) hydrogels for pH dependent colon targeted drug delivery. J. Mater. Sci. Mater. Med., 2009, 20 Suppl 1, S137-146.
165. Casadei, M. A.; Pitarresi, G.; Calabrese, R.; Paolicelli, P.; Giammona, G. Biodegradable and pH-sensitive hydrogels for potential colon-specific drug delivery: characterization and in vitro release studies. Biomacromolecules, 2008, 9, 43-49.
166. Krogars, K.; Heinamaki, J.; Vesalahti, J.; Marvola, M.; Antikainen, O.; Yliruusi, J. Extrusion-spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery. Int. J. Pharm., 2000, 199, 187-194.
167. Hamidi, M.; Azadi, A.; Rafiei, P. Hydrogel nanoparticles in drug delivery. Adv. Drug Deliv. Rev., 2008, 60, 1638-1649.
168. Miller, A. C.; Bershteyn, A.; Tan, W.; Hammond, P. T.; Cohen, R. E.; Irvine, D. J. Block copolymer micelles as nanocontainers for controlled release
169. Ould-Ouali, L.; Arien, A.; Rosenblatt, J.; Nathan, A.; Twaddle, P.; Matalenas, T.; Borgia, M.; Arnold, S.; Leroy, D.; Dinguizli, M.; Rouxhet, L.; Brewster, M.; Preat, V. Biodegradable self-assembling PEG-copolymer as vehicle for poorly water-soluble drugs. Pharm. Res., 2004, 21, 1581-1590.
170. Savic, R.; Luo, L.; Eisenberg, A.; Maysinger, D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science, 2003, 300, 615-618.
171. Croy, S. R.; Kwon, G. S. Polymeric micelles for drug delivery. Curr. Pharm. Des., 2006, 12, 4669-4684.
172. Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res., 2007, 24, 1029-1046.
173. Gaucher, G.; Satturwar, P.; Jones, M. C.; Furtos, A.; Leroux, J. C. Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm., 2010, 76, 147-158.
174. Trivedi, R.; Kompella, U. B. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond), 2010, 5, 485-505.
175. Luo, L.; Tam, J.; Maysinger, D.; Eisenberg, A. Cellular internalization of poly (ethylene oxide)-b-poly (epsilon-caprolactone) diblock copolymer micelles. Bioconjug. Chem., 2002, 13, 1259-1265.
176. Collnot, E. M.; Baldes, C.; Wempe, M. F.; Hyatt, J.; Navarro, L.; Edgar, K. J.; Schaefer, U. F.; Lehr, C. M. Influence of vitamin E TPGS poly (ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Release, 2006, 111, 35-40.
177. Sahay, G.; Gautam, V.; Luxenhofer, R.; Kabanov, A. V. The utilization of pathogen-like cellular trafficking by single chain block copolymer. Biomaterials, 2010, 31, 1757-1764.
178. Canal, F.; Sanchis, J.; Vicent, M. J. Polymer-drug conjugates as nano-sized medicines. Curr. Opin. Biotechnol., 2010, 22, 894-900.
179. Etrych, T.; Kovar, L.; Strohalm, J.; Chytil, P.; Rihova, B.; Ulbrich, K. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. J. Control. Release, 2011, 154, 241-248.
180. Sanchis, J.; Canal, F.; Lucas, R.; Vicent, M. J. Polymer-drug conjugates for novel molecular targets. Nanomedicine (Lond), 2011, 5, 915-935.
181. Anwar, M.; Warsi, M. H.; Mallick, N.; Akhter, S.; Gahoi, S.; Jain, G. K.; Talegaonkar, S.; Ahmad, F. J.; Khar, R. K. Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. Eur. J. Pharm. Sci., 2011, 44, 241-249.
182. Grover, G. N.; Maynard, H. D. Protein-polymer conjugates: synthetic approaches by controlled radical polymerizations and interesting applications. Curr. Opin. Chem. Biol., 2010, 14, 818-827.
183. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov., 2003, 2, 347-360.
184. Lee, E.; Lee, J.; Lee, I. H.; Yu, M.; Kim, H.; Chae, S. Y.; Jon, S. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem., 2008, 51, 6442-6449.
185. Vicent, M. J.; Duncan, R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol., 2006, 24, 39-47.
186. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2, 751-760.
187. Chuang, V. T.; Kragh-Hansen, U.; Otagiri, M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res., 2002, 19, 569-577.
188. Kitchens, K. M.; Kolhatkar, R. B.; Swaan, P. W.; Ghandehari, H. Endocytosis inhibitors prevent poly (amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol. Pharm., 2008, 5, 364-369.
189. Kaminskas, L. M.; Boyd, B. J.; Porter, C. J. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine (Lond), 2011, 6, 1063-1084.
190. Tomalia, D. A.; Reyna, L. A.; Svenson, S. Dendrimers as multipurpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans., 2007, 35, 61-67.
191. D'Emanuele, A.; Attwood, D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev., 2005, 57, 2147-2162.
192. Roberts, J. C.; Bhalgat, M. K.; Zera, R. T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res., 1996, 30, 53-65.
193. Jevprasesphant, R.; Penny, J.; Attwood, D.; McKeown, N. B.; D'Emanuele, A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res., 2003, 20, 1543-1550.
194. Parveen, S.; Sahoo, S. K. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin. Pharmacokinet., 2006, 45, 965-988.
195. El-Sayed, M.; Ginski, M.; Rhodes, C.; Ghandehari, H. Influence of surface chemistry of poly (amidoamine) dendrimers on Caco-2 cell monolayers. J. Bioact. Compat. Polym., 2003, 18, 7-22.
196. Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials, 2003, 24, 1121-1131.
197. Wiwattanapatapee, R.; Carreno-Gomez, B.; Malik, N.; Duncan, R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm. Res., 2000, 17, 991-998.
198. D'Emanuele, A.; Jevprasesphant, R.; Penny, J.; Attwood, D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control. Release, 2004, 95, 447-453.
199. Goldberg, D. S.; Vijayalakshmi, N.; Swaan, P. W.; Ghandehari, H. G3. 5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J. Control. Release, 2011, 150, 318-325.
200. Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. Synthesis, characterization and stability of dendrimer prodrugs. Int. J. Pharm., 2006, 308, 175-182.
201. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev., 2005, 57, 2215-2237.
202. Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int. J. Pharm., 2007, 336, 183-190.
203. El-Sayed, M.; Rhodes, C. A.; Ginski, M.; Ghandehari, H. Transport mechanism (s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int. J. Pharm., 2003, 265, 151-157.
204. El-Sayed, M.; Ginski, M.; Rhodes, C.; Ghandehari, H. Transepithelial transport of poly (amidoamine) dendrimers across Caco-2 cell monolayers. J. Control. Release, 2002, 81, 355-365.
205. Cai, S.; Yang, Q.; Bagby, T. R.; Forrest, M. L. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2011, 63, 901-908.
206. Mufamadi, M. S.; Pillay, V.; Choonara, Y. E.; Du Toit, L. C.; Modi, G.; Naidoo, D.; Ndesendo, V. M. A review on composite liposomal technologies for specialized drug delivery. J. Drug Deliv., 2011, 2011, 939851.
207. Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferrari, M.; Fuchs, H. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl., 2009, 48, 872-897.
208. Romero, E. L.; Morilla, M. J. Topical and mucosal liposomes for vaccine delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2011, 3, 356-375.
209. Hofheinz, R. D.; Gnad-Vogt, S. U.; Beyer, U.; Hochhaus, A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs, 2005, 16, 691-707.
210. Jesorka, A.; Orwar, O. Liposomes: technologies and analytical applications. Annu. Rev. Anal. Chem. (Palo Alto Calif), 2008, 1, 801-832.
211. van Hoogevest, P.; Liu, X.; Fahr, A. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. Expert Opin. Drug Deliv., 2011, 8, 1481-1500.
212. Chen, Y.; Lu, Y.; Chen, J.; Lai, J.; Sun, J.; Hu, F.; Wu, W. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int. J. Pharm., 2009, 376, 153-160.
213. Arien, A.; Henry-Toulme, N.; Dupuy, B. Calcitonin-loaded liposomes: stability under acidic conditions and bile salts-induced disruption resulting in calcitonin-phospholipid complex formation. Biochim. Biophys. Acta, 1994, 1193, 93-100.
214. Khalil, I. A.; Kogure, K.; Futaki, S.; Harashima, H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem., 2006, 281, 3544-3551.
215. Fujiwara, T.; Akita, H.; Harashima, H. Intracellular fate of octaarginine-modified liposomes in polarized MDCK cells. Int. J. Pharm., 2010, 386, 122-130.
216. Muller, R. H.; Shegokar, R.; Keck, C. M. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol., 2011, 8, 207-227.
217. Parhi, R.; Suresh, P. Preparation and Characterization of Solid Lipid Nanoparticles - a Review. Curr. Drug Discov. Technol., 2012, 9, 2-16.
218. Joshi, M. D.; Muller, R. H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm., 2009, 71, 161-172.
219. Bunjes, H. Lipid nanoparticles for the delivery of poorly watersoluble drugs. J. Pharm. Pharmacol., 2010, 62, 1637-1645.
220. Pandey, R.; Sharma, S.; Khuller, G. K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb), 2005, 85, 415-420.
221. Muchow, M.; Maincent, P.; Muller, R. H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm., 2008, 34, 1394-1405.
222. Severino, P.; Andreani, T.; Macedo, A. S.; Fangueiro, J. F.; Santana, M. H.; Silva, A. M.; Souto, E. B. Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. J. Drug Deliv., 2011, 2012, 750891.
223. Setthacheewakul, S.; Mahattanadul, S.; Phadoongsombut, N.; Pichayakorn, W.; Wiwattanapatapee, R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur. J. Pharm. Biopharm., 2010, 76, 475-485.
224. Zhao, Y.; Wang, C.; Chow, A. H.; Ren, K.; Gong, T.; Zhang, Z.; Zheng, Y. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: formulation and bioavailability studies. Int. J. Pharm., 2010, 383, 170-177.
225. Kohli, K.; Chopra, S.; Dhar, D.; Arora, S.; Khar, R. K. Selfemulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov. Today, 2010, 15, 958-965.
226. Date, A. A.; Desai, N.; Dixit, R.; Nagarsenker, M. Selfnanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine (Lond), 2010, 5, 1595-1616.
227. Guo, F.; Zhong, H.; He, J.; Xie, B.; Liu, F.; Xu, H.; Liu, M.; Xu, C. Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation. Arch. Pharm. Res., 2010, 34, 1113-1123.
228. Muller, R. H.; Runge, S. A.; Ravelli, V.; Thunemann, A. F.; Mehnert, W.; Souto, E. B. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm., 2008, 68, 535-544.
229. Nazzal, S.; Khan, M. A. Controlled release of a self-emulsifying formulation from a tablet dosage form: stability assessment and optimization of some processing parameters. Int. J. Pharm., 2006, 315, 110-121.
230. Qi, X.; Wang, L.; Zhu, J.; Hu, Z.; Zhang, J. Self-doubleemulsifying drug delivery system (SDEDDS): a new way for oral delivery of drugs with high solubility and low permeability. Int. J. Pharm., 2011, 409, 245-251.
231. Silva, B. F.; Marques, E. F.; Olsson, U.; Linse, P. Size, shape, and charge of salt-free catanionic microemulsion droplets: a smallangle neutron scattering and modeling study. J. Phys. Chem. B, 2009, 113, 10230-10239.
232. Sezgin, Z.; Yuksel, N.; Baykara, T. Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int. J. Pharm., 2007, 332, 161-167.
233. Dabholkar, R. D.; Sawant, R. M.; Mongayt, D. A.; Devarajan, P. V.; Torchilin, V. P. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm., 2006, 315, 148-157.
234. Ould-Ouali, L.; Noppe, M.; Langlois, X.; Willems, B.; Te Riele, P.; Timmerman, P.; Brewster, M. E.; Arien, A.; Preat, V. Self-assembling PEG-p (CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. J. Control. Release, 2005, 102, 657-668.
235. Ke, W.; Zhao, Y.; Huang, R.; Jiang, C.; Pei, Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J. Pharm. Sci., 2008, 97, 2208-2216.
236. Mutlu, N. B.; Degim, Z.; Yilmaz, S.; Essiz, D.; Nacar, A. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev. Ind. Pharm., 2011, 37, 775-789.
237. Rao, S. V.; Agarwal, P.; Shao, J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro transport study. Int. J. Pharm., 2008, 362, 10-15.
238. Rekha, M. R.; Sharma, C. P. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J. Control. Release, 2009, 135, 144-151.
239. Jin, Y.; Song, Y.; Zhu, X.; Zhou, D.; Chen, C.; Zhang, Z.; Huang, Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials, 2012, 33, 1573-1582.
240. Khutoryanskiy, V. V. Advances in mucoadhesion and mucoadhesive polymers. Macromol. Biosci., 2010, 11, 748-764.
241. Jia, L. Nanoparticle Formulation Increases Oral Bioavailability of Poorly Soluble Drugs: Approaches Experimental Evidences and Theory. Curr. Nanosci., 2005, 1, 237-243.
242. Ensign, L. M.; Cone, R.; Hanes, J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev., 2011.
243. Montisci, M. J.; Giovannuci, G.; Duchene, D.; Ponchel, G. Covalent coupling of asparagus pea and tomato lectins to poly (lactide) microspheres. Int. J. Pharm., 2001, 215, 153-161.
244. Salman, H. H.; Gamazo, C.; Agueros, M.; Irache, J. M. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles. Vaccine, 2007, 25, 8123-8132.
245. Salman, H. H.; Gamazo, C.; de Smidt, P. C.; Russell-Jones, G.; Irache, J. M. Evaluation of bioadhesive capacity and immunoadjuvant properties of vitamin B (12)-Gantrez nanoparticles. Pharm. Res., 2008, 25, 2859-2868.
246. Ramos, H. C.; Rumbo, M.; Sirard, J. C. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol., 2004, 12, 509-517.
247. Pielage, J. F.; Cichon, C.; Greune, L.; Hirashima, M.; Kucharzik, T.; Schmidt, M. A. Reversible differentiation of Caco-2 cells reveals galectin-9 as a surface marker molecule for human follicle-associated epithelia and M cell-like cells. Int. J. Biochem. Cell Biol., 2007, 39, 1886-1901.
248. Mundargi, R. C.; Babu, V. R.; Rangaswamy, V.; Patel, P.; Aminabhavi, T. M. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. J. Control. Release, 2008, 125, 193-209.
249. Mantis, N. J.; Cheung, M. C.; Chintalacharuvu, K. R.; Rey, J.; Corthesy, B.; Neutra, M. R. Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. J. Immunol., 2002, 169, 1844-1851.
250. Frey, A.; Giannasca, K. T.; Weltzin, R.; Giannasca, P. J.; Reggio, H.; Lencer, W. I.; Neutra, M. R. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med., 1996, 184, 1045-1059.
251. Hamzaoui, N.; Kerneis, S.; Caliot, E.; Pringault, E. Expression and distribution of beta1 integrins in in vitro-induced M cells: implications for Yersinia adhesion to Peyer's patch epithelium. Cell Microbiol., 2004, 6, 817-828.
252. Salman, H. H.; Gamazo, C.; Campanero, M. A.; Irache, J. M. Salmonella-like bioadhesive nanoparticles. J. Control. Release, 2005, 106, 1-13.
253. Shakweh, M.; Ponchel, G.; Fattal, E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv., 2004, 1, 141-163.
254. Dong, Y.; Feng, S. S. Poly (d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials, 2005, 26, 6068-6076.
255. Takeuchi, H.; Thongborisute, J.; Matsui, Y.; Sugihara, H.; Yamamoto, H.; Kawashima, Y. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv. Drug Deliv. Rev., 2005, 57, 1583-1594.
256. Desai, M. P.; Labhasetwar, V.; Amidon, G. L.; Levy, R. J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res., 1996, 13, 1838-1845.
257. Vila, A.; Gill, H.; McCallion, O.; Alonso, M. J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Control. Release, 2004, 98, 231-244.
258. Bhavsar, M. D.; Amiji, M. M. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS Pharm-SciTech., 2008, 9, 288-294.
259. Bhavsar, M. D.; Amiji, M. M. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release, 2007, 119, 339-348.
260. Mori, S.; Matsuura, A.; Rama Prasad, Y. V.; Takada, K. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol. Pharm. Bull., 2004, 27, 418-421.
261. Thanou, M.; Verhoef, J. C.; Junginger, H. E. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev., 2001, 52, 117-126.
262. des Rieux, A.; Ragnarsson, E. G.; Gullberg, E.; Preat, V.; Schneider, Y. J.; Artursson, P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci., 2005, 25, 455-465.
263. Jani, P.; Halbert, G. W.; Langridge, J.; Florence, A. T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol., 1989, 41, 809-812.
264. Woodley, J. Bioadhesion: new possibilities for drug administration? Clin. Pharmacokinet., 2001, 40, 77-84.
265. Chayed, S.; Winnik, F. M. In vitro evaluation of the mucoadhesive properties of polysaccharide-based nanoparticulate oral drug delivery systems. Eur. J. Pharm. Biopharm., 2007, 65, 363-370.
266. Sakuma, S.; Sudo, R.; Suzuki, N.; Kikuchi, H.; Akashi, M.; Ishida, Y.; Hayashi, M. Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. J. Control. Release, 2002, 81, 281-290.
267. Sadeghi, A. M.; Dorkoosh, F. A.; Avadi, M. R.; Weinhold, M.; Bayat, A.; Delie, F.; Gurny, R.; Larijani, B.; Rafiee-Tehrani, M.; Junginger, H. E. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm., 2008, 70, 270-278.
268. Lichtenberger, L. M. The hydrophobic barrier properties of gastrointestinal mucus. Annu. Rev. Physiol., 1995, 57, 565-583.
269. Norris, D. A.; Puri, N.; Sinko, P. J. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev., 1998, 34, 135-154.
270. Dawson, M.; Wirtz, D.; Hanes, J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J. Biol. Chem., 2003, 278, 50393-50401.
271. Foster, N.; Hirst, B. H. Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deliv. Rev., 2005, 57, 431-450.
272. Henke, M. O.; Ratjen, F. Mucolytics in cystic fibrosis. Paediatr. Respir. Rev., 2007, 8, 24-29.
273. Albanese, C. T.; Cardona, M.; Smith, S. D.; Watkins, S.; Kurkchubasche, A. G.; Ulman, I.; Simmons, R. L.; Rowe, M. I. Role of intestinal mucus in transepithelial passage of bacteria across the intact ileum in vitro. Surgery, 1994, 116, 76-82.
274. Costantini, T. W.; Putnam, J. G.; Sawada, R.; Baird, A.; Loomis, W. H.; Eliceiri, B. P.; Bansal, V.; Coimbra, R. Targeting the gut barrier: identification of a homing peptide sequence for delivery into the injured intestinal epithelial cell. Surgery, 2009, 146, 206-212.
275. Jain, A.; Gupta, Y.; Jain, S. K. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J. Pharm. Pharm. Sci., 2007, 10, 86-128.
276. Gupta, Y.; Jain, A.; Jain, P.; Jain, S. K. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J. Drug Target, 2007, 15, 231-240.
277. Jain, A.; Jain, S. K. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur. J. Pharm. Sci., 2008, 35, 404-416.
278. Francis, M. F.; Cristea, M.; Winnik, F. M. Exploiting the vitamin B12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules, 2005, 6, 2462-2467.
279. Bimbo, L. M.; Peltonen, L.; Hirvonen, J.; Santos, H. A. Toxicological profile of therapeutic nanodelivery systems. Curr. Drug Metab., 2012, 13, 1068-1086.
280. Jones, C. F.; Grainger, D. W. In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev., 2009, 61, 438-456.
281. Oberdorster, G.; Oberdorster, E.; Oberdorster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect., 2005, 113, 823-839.
282. Arora, S.; Rajwade, J. M.; Paknikar, K. M. Nanotoxicology and in vitro studies: The need of the hour. Toxicol. Appl. Pharmacol., 2011, 258, 151-165.
283. Powell, J. J.; Faria, N.; Thomas-McKay, E.; Pele, L. C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J. Autoimmun., 2010, 34, J226-233.
284. Fernandez-Carballido, A.; Pastoriza, P.; Barcia, E.; Montejo, C.; Negro, S. PLGA/PEG-derivative polymeric matrix for drug delivery system applications: Characterization and cell viability studies. Int. J. Pharm., 2008, 352, 50-57.